$0 is the total value of Burrage Capital Management LLC's 1 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 104.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | 00 | $0 | – | 0 | +100.0% | 0.00% | – | |
| TPTX | Exit | TURNING POINT THERAPEUTICS I | $0 | – | -2,164 | -100.0% | -0.17% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -47,708 | -100.0% | -1.05% | – |
| BDTX | Exit | BLACK DIAMOND THERAPEUTICS I | $0 | – | -110,447 | -100.0% | -1.35% | – |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -50,000 | -100.0% | -1.59% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -244,920 | -100.0% | -2.18% | – |
| GERN | Exit | GERON CORP | $0 | – | -1,912,673 | -100.0% | -2.70% | – |
| MRUS | Exit | MERUS N V | $0 | – | -130,683 | -100.0% | -2.76% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -705,585 | -100.0% | -2.88% | – |
| ADCT | Exit | ADC THERAPEUTICS SA | $0 | – | -124,875 | -100.0% | -3.05% | – |
| MIRM | Exit | MIRUM PHARMACEUTICALS INC | $0 | – | -205,866 | -100.0% | -3.57% | – |
| YMAB | Exit | Y-MABS THERAPEUTICS INC | $0 | – | -114,454 | -100.0% | -3.88% | – |
| INZY | Exit | INOZYME PHARMA INC | $0 | – | -242,517 | -100.0% | -4.14% | – |
| HRMY | Exit | HARMONY BIOSCIENCES HLDGS IN | $0 | – | -150,000 | -100.0% | -4.24% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -4.83% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -244,673 | -100.0% | -4.86% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -294,620 | -100.0% | -5.57% | – |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -2,331,313 | -100.0% | -6.66% | – |
| NEO | Exit | NEOGENOMICS INC | $0 | – | -147,921 | -100.0% | -6.70% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -237,442 | -100.0% | -6.80% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -836,802 | -100.0% | -6.97% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -63,634 | -100.0% | -10.33% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -864,916 | -100.0% | -13.71% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.